Health-related quality of life and utilities in gastric premalignant conditions and malignant lesions: a multicentre study in a high prevalence country

A recent review of economic studies relating to gastric cancer revealed that authors use different tests to estimate utilities in patients with and without gastric cancer. Our aim was to determine the utilities of gastric premalignant conditions and adenocarcinoma with a single standardized health m...

Full description

Saved in:
Bibliographic Details
Published in:Journal of gastrointestinal and liver diseases : JGLD Vol. 23; no. 4; pp. 371 - 378
Main Authors: Areia, Miguel, Alves, Susana, Brito, Daniel, Cadime, Ana Teresa, Carvalho, Rita, Saraiva, Sandra, Ferreira, Sara, Moleiro, Joana, Pereira, António Dias, Carrasquinho, João, Lopes, Luís, Ramada, José, Marcos-Pinto, Ricardo, Pedroto, Isabel, Contente, Luís, Eliseu, Liliana, Vieira, Ana Margarida, Sampaio, Margarida, Sousa, Helena Tavares, Almeida, Nuno, Gregório, Carlos, Portela, Francisco, Sofia, Carlos, Braga, Vânia, Baginha, Elisabete, Bana e Costa, Tiago, Chagas, Cristina, Mendes, Luís Lebre, Magalhães-Costa, Pedro, Matos, Leopoldo, Gonçalves, Francisco Rocha, Dinis-Ribeiro, Mário
Format: Journal Article
Language:English
Published: Romania 01-12-2014
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A recent review of economic studies relating to gastric cancer revealed that authors use different tests to estimate utilities in patients with and without gastric cancer. Our aim was to determine the utilities of gastric premalignant conditions and adenocarcinoma with a single standardized health measure instrument. Cross-sectional nationwide study of patients undergoing upper endoscopy (n=1,434) using the EQ-5D-5L quality of life (QoL) questionnaire. According to EQ-5D-5L, utilities in individuals without gastric lesions were 0.78 (95% confidence interval: 0.76-0.80), with gastric premalignant conditions 0.79 (0.77-0.81), previously treated for gastric cancer 0.77 (0.73-0.81) and with present cancer 0.68 (0.55-0.81). Self-reported QoL according to the visual analogue scale (VAS) for the same groups were 0.67 (0.66-0.69), 0.67 (0.66-0.69), 0.62 (0.59-0.65) and 0.62 (0.54-0.70) respectively. Utilities were consistently lower in women versus men (no lesions 0.71 vs. 0.78; premalignant conditions 0.70 vs. 0.82; treated for cancer 0.72 vs. 0.78 and present cancer 0.66 vs. 0.70). The health-related QoL utilities of patients with premalignant conditions are similar to those without gastric diseases whereas patients with present cancer show decreased utilities. Moreover, women had consistently lower utilities than men. These results confirm that the use of a single standardized instrument such as the EQ-5D-5L for all stages of the gastric carcinogenesis cascade is feasible and that it captures differences between conditions and gender dissimilarities, being relevant information for authors pretending to conduct further cost-utility analysis.
ISSN:1841-8724
1842-1121
DOI:10.15403/jgld.2014.1121.234.hrq